The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | The prognostic significance of genomic complexity in patients with CLL
Ellinor Goergen, MD, University Hospital Cologne, Cologne, Germany, comments on the prognostic significance of genomic complexity in patients with chronic lymphocytic leukemia (CLL). She states that genomic complexity, defined as three or more chromosomal aberrations, has a negative impact on prognosis. Dr Goergen notes that targeted therapies have been shown to benefit patients, but the effect of continuous BTK inhibition is still unclear, requiring further study. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
So we know that the genomic complexity is defined as like three or more genetic aberrations or chromosomal aberrations in the patient’s genome. And we know that it has an impact, especially looking at the chemoimmunotherapy era, where patients were treated a lot with FCR or BR, for example. And we know that it has a negative impact on prognosis. So in recent data or literature at the moment is showing us that there’s a lot to be gained with treating the patients with targeted therapies...
So we know that the genomic complexity is defined as like three or more genetic aberrations or chromosomal aberrations in the patient’s genome. And we know that it has an impact, especially looking at the chemoimmunotherapy era, where patients were treated a lot with FCR or BR, for example. And we know that it has a negative impact on prognosis. So in recent data or literature at the moment is showing us that there’s a lot to be gained with treating the patients with targeted therapies. What we don’t know yet, or the data is not super clear at the moment, on continuous BTK inhibition in these patients. So this is definitely something that needs to be studied further. But we do see that the targeted therapies that are basically now a standard of care in most places, actually that the patients profit from it. And I think there’s also an interesting talk here at this meeting being presented about how TP53 mutations or homozygotic mutations or aberrations are outweighed kind of by the complex karyotype. So complex karyotype becomes more and more of a prognostic impact or has a prognostic impact and should be assessed more frequently.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
AstraZeneca: Honoraria; AbbVie: Honoraria.
